Changes in Ratings
is upgraded at JPMorgan. New CEO should help drive higher earnings growth through better capital allocation.
coverage is initiated at UBS with a buy rating. Price target starts at $18 with fiscal year 2008 EPS estimates set at a -89 cents.
is upgraded to a buy at Merrill Lynch, with a $46 price target. The company is cutting costs, and the U.S. business has remained resilient so far.
is downgraded at Merrill from neutral to sell. The company will struggle as consumer credit and spending will likely continue to deteriorate in the coming quarters.
is upgraded to neutral at JPMorgan. Management has improved execution, and the company appears to be on a clear path to double-digit annual earnings growth.
is upgraded to buy from neutral at Goldman Sachs.Goldman said the upgrade is due to business momentum and potential for margin upside. The investment bank believes cash flow will catch up to robust net income growth in early 2008. Price target raised to $33 from $32.
is downgraded from overweight to underweight at Morgan Stanley, which moves its price target from $88 to $45.
Capital One was also downgraded from neutral to sell at Merrill. The stock has already been hit, but further market deterioration reduces the likelihood that the company could be bought.
was upgraded from neutral to outperform at Robert Baird which set a $42 price target. Baird said the company has reached a cyclical inflection point, and the stock is likely to regain its premium earnings multiple.
is downgraded from neutral to sell at Merrill. The stock has the most downside potential in the group, because of its increased credit sensitivity.
Fresh Del Monte Produce
coverage is initiated at Morgan Stanley with an overweight rating and a $38 price target.
( HANS) is initiated at UBS with a buy rating. Price target starts at $58, with FY 2008 EPS estimates set at $2.10.
is upgraded from neutral to outperform at Baird, with a $24 price target. Baird said that 70% of the company's end markets appear stable, and margins should improve through restructuring efforts.
is downgraded to a hold rating at Deutsche Bank, as JV risk is likely to persist.
( MFE) is downgraded from outperform to market perform at Friedman, Billings Ramsey. It's a valuation call, as the stock is up 40% on the year. FBR set a $43 price target.
is upgraded from hold to buy at Deutsche Bank, which set a $32 price target. The company posted a strong quarter, and margins and operating cash flow should continue to grow. Estimates were also raised.
is upgraded to a buy rating from hold at Jefferies. Price target jumps to $170 from $105, and the FY 2008 EPS estimate lifts to $2.13 from $2.10.
is downgraded from buy to neutral at Banc of America, with a $56 price target. Recent sales trends have hurt margins and lowered the visibility for 2008.
Stock Comments / EPS Changes
( ESLR) numbers are raised at Jefferies. Price target lifts to $12 from $10, and FY 2008 EPS estimates raised to a loss of 11 cents from a loss of 13 cents. Jefferies reiterates its hold rating.
numbers are raised at Jefferies. Price target lifts to $30 from $25, and FY 2008 EPS estimates upped to 93 cents from 90 cents. Reiterates buy rating.
estimates are trimmed at Goldman to $3.92 from $3.95. Management introduced 2008 guidance of $3.85 to $4.00 at its annual analyst meeting. Note shift in Zyprexa patent expiry to November 20011 from April 2011. Maintained buy rating and $61 target.
( PALM) 2008 EPS estimates slashed at Credit Suisse, to a loss of 11 cents from a gain of 11 cents after company lowered FQ2 guidance. Sees benefits from rapid smartphone growth, but competition will continue to adversely affect market share and operating margins. Maintained neutral rating.